Free shipping on all orders over $ 500

Others Others

Cat.No.  Name Information
M2206 TH-302 (Evofosfamide) TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM.
M6098 Baicalein Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM.
M9325 EGTA EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages.
M9330 Brij-35 Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability.
M6154 2-PMPA tetrasodium 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM.
M2250 Pamidronate disodium Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis.
M9916 DPPH DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants.
M9194 Insulin (human) Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets.
M3409 Formestane Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM.
M9665 N-(2-amino-2-oxoethyl)acrylamide N-(2-Amino-2-oxoethyl)acrylamide
M24751 Domagrozumab Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD).
M24742 Selicrelumab Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.
M24723 Rozanolixizumab Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.
M24719 Tezepelumab Tezepelumab (AMG 157) is a first-in-class human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma.
M24701 Zolbetuximab Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
M24663 Tisotumab Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors.
M24644 Temelimab Temelimab (GNbAC-1) is an IgG4 monoclonal antibody that targets the human endogenous retroviral envelope protein HERV-W-Env.
M24642 Landogrozumab Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease.
M24629 Idarucizumab Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
M24623 Enoblituzumab Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators.
M24613 Anifrolumab Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
M24612 Ligelizumab Ligelizumab (QGE 031) is a humanized high-affinity monoclonal anti-IgE antibody. Ligelizumab can be used for the research of chronic spontaneous urticarial.
M24605 Concizumab Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
M24551 Itolizumab Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.
M24545 Samalizumab Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.
M22514 Elotuzumab Elotuzumab is a First-in-Class monoclonal antibody directed against the SLAMF7 receptor, it specifically binds to signaling lymphocyte activating molecule family member 7 (SLAMF7) and activates the body's immune response to attack and kill multiple myeloma cells. Elotuzumab exerts its anti-myeloma effects mainly through ADCC and activation of NK cells.
M22461 1-Boc-3-AMino-4-fluoropyrrolidine 1-Boc-3-AMino-4-fluoropyrrolidine
M22460 UDP-glucuronic acid trisodium UDP-​glucuronic acid (UDPGA) trisodium is a critical precursor for essential glycoconjugates across biological kingdoms, ranging from mammalian glycosaminoglycans and plant cell wall polysaccharides to bacterial capsule glycoglycerolipids.
M22455 PLGA lactide:glycolide (50:50) MW 120000 Poly(D,L-lactide-co-glycolide) is a synthetic amino acid that has been used to deliver macromolecular therapeutics.
M22446 Ferrous Bisglycinate Ferrous Bisglycinate




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.